Awards & Advancement

Pete Nicholas to retire at Boston Scientific

Monday, February 29, 2016

Pete M. Nicholas, the company’s co-founder and chairman of its board, will retire from the board of Boston Scientific in May. Nicholas served as Boston Scientific’s chief executive officer and co-chairman of the board since its founding in 1979. In 1995, Pete stepped down as CEO and became its chairman. During his almost 40 years of leadership, the company grew to become a global leader in the field of interventional medicine, improving the lives of patients worldwide.

[Read More]

Christel Bories fired by Ipsen’s board over strategy disagreement

Tuesday, February 23, 2016

Christel Bories, deputy CEO, has left Ipsen. Since her arrival in February 2013, Christel Bories has made a significant contribution to the operational transformation and improved results of Ipsen. Recently, the board of directors and Christel Bories have noted disagreements over the group’s strategy. In accordance with the Afep-Medef corporate governance code, the board of directors has decided to grant the contractually agreed severance package to Christel Bories.

[Read More]

Mannkind executive chairman Alfred Mann steps down

Friday, February 19, 2016

Alfred E. Mann has resigned as executive chairman and as a board member of MannKind, effective immediately. MannKind named Kent Kresa as chairman of the board and also named Mann as chairman emeritus of MannKind. Mann will continue to advise the company as an employee in a non-executive capacity. 

[Read More]

Tocagen appoints Wood VP, regulatory affairs and quality assurance

Friday, February 19, 2016

Tocagen, a clinical-stage, cancer-selective gene therapy company, has named John Wood vice president of regulatory affairs and quality assurance. Wood holds more than 20 years of regulatory affairs experience focusing on first-in-class drugs for diseases with high unmet need. While at IDEC Pharmaceuticals, he played a leading role, in close collaboration with Genentech, in the first regulatory approval of RITUXAN for the treatment of immune system B-cell malignancies.

[Read More]